<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720326</url>
  </required_header>
  <id_info>
    <org_study_id>EnGraft</org_study_id>
    <secondary_id>2020-000796-20</secondary_id>
    <nct_id>NCT04720326</nct_id>
  </id_info>
  <brief_title>Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients</brief_title>
  <official_title>Multicentre, Open-Label, Randomised, Two-Arm, Parallel-Group, Superiority Study to Assess Bioavailability and Practicability of Envarsus® Compared With Advagraf® in de Novo Liver Transplant Recipients (EnGraft)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Geissler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Excelya Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial participants are randomised within 14 days after liver transplantation surgery in a 1:1&#xD;
      ratio to two alternative treatment arms containing either Envarsus® (test arm) or Advagraf®&#xD;
      (comparator arm) as first-line calcineurin inhibitor within a standard-of-care&#xD;
      immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at&#xD;
      regular intervals to assess drug bioavailability and the ease and accuracy of achieving the&#xD;
      targeted blood concentration range. Dose-normalised trough level (concentration/dose ratio)&#xD;
      is measured at 12 weeks post-randomisation as an estimate of tacrolimus bioavailability. It&#xD;
      is hypothesised that treatment with Envarsus® will confer a superior (higher) C/D ratio after&#xD;
      12 weeks of therapy owing to the superior bioavailability of this galenic drug formulation&#xD;
      (proprietary MeltDose® technology). To test whether an elevated C/D ratio is also associated&#xD;
      with improved clinical outcomes, a range of other pharmacokinetic, efficacy and safety&#xD;
      variables are evaluated at 10 study visits spanning a period of 3 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A dynamic allocation technique allocates participants in a 1:1 ratio to one of two treatment arms: Envarsus® tablets (test IMP) or Advagraf® capsules (comparator IMP). Pre-treatment with immediate-release tacrolimus, as well as trial site, are used as stratification factors in the treatment allocation in order to minimise sources of treatment bias.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)</measure>
    <time_frame>12 weeks post-randomisation</time_frame>
    <description>To calculate C/D ratio, &quot;concentration&quot; is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and &quot;dose&quot; is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of IMP dose adjustments</measure>
    <time_frame>Until 12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the first defined range in target trough level</measure>
    <time_frame>Time period measured in days, assessed at 12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of measurements above and below the first defined range in target trough level</measure>
    <time_frame>Time period measured in days, assessed at 12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalised trough level (C/D ratio) during long-term follow-up</measure>
    <time_frame>1, 2 and 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean tacrolimus trough level and inter-patient variability (range) of tacrolimus trough levels</measure>
    <time_frame>1, 2, 4 and 12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-patient variability (range) of tacrolimus total daily dose</measure>
    <time_frame>Until 12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with trough levels lower, within, or higher than the standard reference range</measure>
    <time_frame>1, 2, 4 and 12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of clinically-confirmed biopsy-proven acute rejection</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure (defined as necessity for re-transplantation)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death (for any reason)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure rate (composite endpoint of biopsy-proven acute rejection, graft failure or death)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (composite endpoint of biopsy-proven acute rejection, graft failure or death) after randomisation</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejections requiring treatment</measure>
    <time_frame>12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of multiple rejection episodes</measure>
    <time_frame>12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change versus baseline in laboratory measures of liver function (aspartate transaminase, alanine transaminase, alkaline phosphatase, gamma-glutamyltransferase, bilirubin, albumin, cholinesterase, INR)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change versus baseline in laboratory measures of metabolic profile (triglycerides, HDL cholesterol, LDL cholesterol, total cholesterol, HbA1c, fasting plasma glucose)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change versus baseline in laboratory measures of renal function (creatinine, estimated glomerular filtration rate)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and type of malignancies diagnosed in trial participants</measure>
    <time_frame>1, 2 and 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and type of infections (hepatitis C virus, hepatitis B virus, cytomegalovirus, Epstein-Barr virus) experienced by trial participants</measure>
    <time_frame>1, 2 and 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of liver fibrosis (fibroscan or biopsy)</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, type, severity, seriousness and causality of adverse events (AEs)</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change versus baseline in heart rate</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change versus baseline in blood pressure</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change versus baseline in body weight</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of de novo occurrence of tremor or vision impairments</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-transplant diabetes mellitus and post-transplant hyperglycaemia</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalised trough level (C/D ratio)</measure>
    <time_frame>12 weeks post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and doses of immunosuppressive medications (incl. other tacrolimus formulations)</measure>
    <time_frame>At 12 weeks and after 12 weeks (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of primary hepatic disease</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of donor-specific antibodies</measure>
    <time_frame>12 weeks and 1, 2, 3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation rate</measure>
    <time_frame>12 weeks post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and time to study treatment discontinuation</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patient withdrawal from the study</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to patient withdrawal from the study</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for patient withdrawal from the study</measure>
    <time_frame>3 years post-randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Prophylaxis Against Liver Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Envarsus®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take prolonged-release tacrolimus tablets orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advagraf®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants take prolonged-release tacrolimus capsules orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Pill</intervention_name>
    <description>Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.</description>
    <arm_group_label>Envarsus®</arm_group_label>
    <other_name>Envarsus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus capsule</intervention_name>
    <description>Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.</description>
    <arm_group_label>Advagraf®</arm_group_label>
    <other_name>Advagraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated written informed consent&#xD;
&#xD;
          2. Adult (≥18 years old) male or female&#xD;
&#xD;
          3. Recipient of a whole liver transplant from a deceased donor or a split liver&#xD;
             transplant from a deceased or living donor&#xD;
&#xD;
          4. ABO blood type compatible with the organ donor&#xD;
&#xD;
          5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multi-organ transplantation&#xD;
&#xD;
          2. Any previous organ allograft transplantation&#xD;
&#xD;
          3. Biopsy-proven acute rejection that is ongoing at the time of randomisation&#xD;
&#xD;
          4. Occurrence of post-transplant thrombosis, occlusion or stent placement in any major&#xD;
             hepatic arteries, hepatic veins, portal vein or inferior vena cava&#xD;
&#xD;
          5. History of extra-hepatic malignancy that could not be curatively treated&#xD;
&#xD;
          6. Hepatocellular carcinoma with extra-hepatic spread or macrovascular invasion&#xD;
&#xD;
          7. Uncontrolled systemic infection&#xD;
&#xD;
          8. Requirement of life support measures such as ventilation or vasopressor agents (&gt;20&#xD;
             µg/kg body weight/h) at the time of randomisation&#xD;
&#xD;
          9. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the&#xD;
             excipients listed in section 6.1 of the Summary of Product Characteristics of both&#xD;
             Envarsus® and Advagraf®, and/or to any other macrolides&#xD;
&#xD;
         10. Ongoing, planned or foreseeable use of cyclosporine or any tacrolimus preparation&#xD;
             other than Envarsus® or Advagraf® (except for immediate-release formulations&#xD;
             administered before randomisation)&#xD;
&#xD;
         11. Any prolonged-release tacrolimus treatment prior to randomisation&#xD;
&#xD;
         12. Pregnant or nursing (lactating) female, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin laboratory test&#xD;
&#xD;
         13. Female of child-bearing potential, defined as physiologically capable of becoming&#xD;
             pregnant, unless using a reliable method of contraception&#xD;
&#xD;
         14. Participation in another interventional clinical trial during the time period from&#xD;
             randomisation to study end, if the trial is testing an Investigational Medicinal&#xD;
             Product or if the intervention and/or follow-up requirements of the trial impede or&#xD;
             interfere with either the objectives of EnGraft or the treatment / follow-up&#xD;
             requirements of EnGraft&#xD;
&#xD;
         15. Any condition or factor which, in the judgement of the investigator, would place the&#xD;
             subject at undue risk, invalidate communication with the investigator or study team,&#xD;
             or hamper compliance with the trial protocol or follow-up schedule&#xD;
&#xD;
         16. Inability to freely give informed consent (e.g. individuals under legal guardianship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans J. Schlitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward K. Geissler, PhD</last_name>
    <phone>+49 941 944</phone>
    <phone_ext>6964</phone_ext>
    <email>edward.geissler@ukr.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf P. Neumann, MD</last_name>
      <phone>+49 241 8089 500</phone>
      <email>uneumann@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Ulf P. Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Pratschke, MD</last_name>
      <phone>+49 30 450 552 001</phone>
      <email>johann.pratschke@charite.de</email>
    </contact>
    <investigator>
      <last_name>Johann Pratschke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Willuweit, MD</last_name>
      <phone>+49 201 723 84611</phone>
      <email>katharina.willuweit@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Katharina Willuweit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas A. Schnitzbauer, MD</last_name>
      <phone>+49 69 6301 5253</phone>
      <email>andreas.schnitzbauer@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Andreas A. Schnitzbauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uta Herden, MD</last_name>
      <phone>+49 40 7410 50822</phone>
      <email>u.herden@uke.de</email>
    </contact>
    <investigator>
      <last_name>Uta Herden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Vondran, MD</last_name>
      <phone>+49 511 532 4091</phone>
      <email>vondran.florian@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Florian Vondran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Rupp, MD</last_name>
      <phone>+49 6221 56 6538</phone>
      <email>christian.rupp@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Christian Rupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Falk Rauchfuss, MD</last_name>
      <phone>+49 3641 9 32 26 66</phone>
      <email>falk.rauchfuss@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Falk Rauchfuss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Braun, MD</last_name>
      <phone>+49 431 500 33420</phone>
      <email>felix.braun@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Felix Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Mittler, MD</last_name>
      <phone>+49 6131 17 2063</phone>
      <email>jens.mittler@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Jens Mittler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Wilms, MD</last_name>
      <phone>+49 251 835 7933</phone>
      <email>christian.wilms@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Christian Wilms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward K. Geissler, PhD</last_name>
      <phone>+49 941 944 6964</phone>
      <email>edward.geissler@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Hans J. Schlitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvio Nadalin, MD</last_name>
      <phone>+49 7071 2986600</phone>
      <email>silvio.nadalin@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Silvio Nadalin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Edward Geissler</investigator_full_name>
    <investigator_title>Head of the Department of Experimental Surgery</investigator_title>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Concentration/dose ratio</keyword>
  <keyword>Immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

